This acquisition enhances Eli Lilly's portfolio, which also includes promising candidates for retinitis pigmentosa and Friedreich's ataxia.
Wednesday, December 10, 2025
Eli Lilly (LLY) Completes Acquisition of Adverum Biotechnologies
Eli Lilly (LLY) Completes Acquisition of Adverum Biotechnologies. GuruFocus News 12/09/2025.
Subscribe to:
Comments (Atom)
